The role of calcium channel blockers on chronic kidney disease

Hsiao Lin Chang, Yea-Huei Kao, Shu Min Kao, Ming-Cheng Wang, Chin-Chung Tseng

研究成果: Article同行評審


Chronic kidney disease (CKD) is a progressive renal disease. According to the data of Department of Health, Executive Yuan, CKD was the eighth leading cause of death in Taiwan in 2003. How to delay the progression of CKD to end-stage renal disease (ESRD) is an important issue. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are the first choice for the treatment in CKD patients with hypertension. Are there alternative drugs to ACEIs or ARBs for renoprotection? Animal studies and clinical trials demonstrated that nondihydropyridine calcium channel blockers (NDHP CCBs), in addition to blood pressure control, could reduce the proteinuria in the presence or absence of diabetes. In the patients unable to tolerate ACEIs and/or ARBs, we can consider the use of NDHP CCBs for the management of blood pressure and renoprotection. Dihydropyridine calcium channel blockers (DHP CCBs) in CKD should be restricted to further lower blood pressure in patients unsatisfactory with ACEIs or ARBs. Ther combination of ACEIs or ARBs and NDHP CCBs is more favorable in alleviating proteinuria and has better blood pressure control than monotherapy.

頁(從 - 到)175-180
期刊Journal of Internal Medicine of Taiwan
出版狀態Published - 2005 11月 24

All Science Journal Classification (ASJC) codes

  • 內科學


深入研究「The role of calcium channel blockers on chronic kidney disease」主題。共同形成了獨特的指紋。